President Donald Trump announced a plan to impose tariffs of up to 200% on imported generic drugs beginning in 2028, with a phased increase starting at 100% in August 2028. The measure is intended to incentivize manufacturers to relocate production to the U.S., though experts remain skeptical about its effectiveness.
Immediate Action & Core Facts
Trump’s proposal includes a two-year runway before tariffs take effect, allowing manufacturers time to adjust. The White House cited policies like full equipment expensing as supporting domestic production. The generic drug industry, however, argues that structural challenges—such as purchasing and reimbursement issues—limit domestic manufacturing.
Deeper Dive & Context
Industry Impact
Generic drugs account for 90% of U.S. prescriptions, with India and China supplying a significant portion. The industry has expanded its U.S. footprint but faces financial hurdles. John Murphy III, CEO of the Association for Accessible Medicines, emphasized the need for policies that stabilize the industry.
Economic and Supply Chain Considerations
The global generic drug market is worth nearly $500 billion. Brand-name drugmakers, with higher margins, may absorb cost increases more easily than generic manufacturers. The U.S. relies heavily on imports for key medications like ibuprofen, acetaminophen, and penicillin.
Expert Skepticism
Marta Wosińska, a senior fellow at the Brookings Institution, stated that tariffs alone are unlikely to drive onshoring. The White House, however, pointed to most-favored-nations deals and Section 232 tariffs as part of a broader strategy.